Evidence map›Paper›PMID 39289329›Full record

ArticleInfectious diseases and therapy2024

A Model-Based Estimation of RSV-Attributable Incidence of Hospitalizations and Deaths in Italy Between 2015 and 2019.

Estelle Méroc, Caihua Liang, Raffaella Iantomasi, Chukwuemeka Onwuchekwa, Giuseppe Pietro Innocenti, Daniela d'Angela, Solomon Molalign, Thao Mai Phuong Tran, Somsuvro Basu, Bradford D Gessner and 3 more

Abstract read
In one paragraph

Article in Infectious diseases and therapy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Estelle MérocP95 Epidemiology and Pharmacovigilance, Leuven, Belgium.
Caihua LiangPfizer Inc, Milan, Italy. caihua.liang@pfizer.com.
Raffaella IantomasiPfizer Inc, Milan, Italy.
Chukwuemeka OnwuchekwaP95 Epidemiology and Pharmacovigilance, Leuven, Belgium.
Giuseppe Pietro InnocentiPfizer Inc, Milan, Italy.
Daniela d'AngelaCentro Per La Ricerca Economica Applicanta in Sanita, Rome, Italy.
Solomon MolalignP95 Epidemiology and Pharmacovigilance, Leuven, Belgium.
Thao Mai Phuong TranP95 Epidemiology and Pharmacovigilance, Leuven, Belgium.
Somsuvro BasuP95 Epidemiology and Pharmacovigilance, Leuven, Belgium.
Bradford D GessnerPfizer Inc, Milan, Italy.
Robin BruyndonckxP95 Epidemiology and Pharmacovigilance, Leuven, Belgium.
Aleksandra Polkowska-KramekP95 Epidemiology and Pharmacovigilance, Leuven, Belgium.
Elizabeth BegierPfizer Inc, Milan, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionRespiratory syncytial virus (RSV) incidence is known to be underestimated in adults due to its infrequent diagnostic testing and lower sensitivity of single nasal/nasopharyngeal swab PCR testing outside of the early childhood period. RSV can trigger acute cardiac events as well as cause respiratory disease. Consequently, we used a model-based study to estimate RSV-attributable hospitalization and mortality incidence among adults in Italy between 2015 and 2019.

methodsThrough a database predisposed by CREA Sanità, by extracting monthly data from the Italian hospitalization collection data of the Ministry of Health and the Italian National Institute of Statistics (ISTAT) data (mortality), we estimated yearly RSV-attributable incidence of events for different cardiorespiratory outcomes. We used a quasi-Poisson regression model, which accounted for periodic and aperiodic time trends and viral activity proxies.

resultsThe yearly RSV-attributable cardiorespiratory hospitalization incidence increased with age and was highest among adults aged ≥ 75 years (1064-1527 cases per 100,000 person-years). Similarly, the RSV-attributable cardiorespiratory mortality rate was highest among persons aged ≥ 75 years (59-85 deaths per 100,000 person-years). Incidence rates for RSV-attributable hospitalizations and RSV-attributable mortality were on average 2-3 times higher for cardiorespiratory than respiratory disease alone. Incidence rate based on RSV-specific ICD codes only were 405-1729 times lower than modeled estimates accounting for untested events.

conclusionRSV causes a substantial disease burden among adults in Italy and contributes to both respiratory and cardiovascular conditions. Our results emphasize the need for effective RSV prevention strategies, particularly among older adults.

Indexed as

Disease burdenHospitalizationIncidenceMortalityRespiratory syncytial virus

Identifiers

PMID39289329
PMCPMC11499556

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.